Recent work identified ZFHX3 mutations as an independent prognostic biomarker of longer OS in NSCLC patients treated with immune checkpoint inhibitors51,52, possibly explained by higher mutational burden and increased tumor immunogenicity52. The gene discussed is ZFHX3; the disease is neoplasm.